Fierce Pharma7d
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
Texas Court Rejects J&J’s Bankruptcy Attempt to End Talc Suits
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the ...
BioSpace5d
Sanofi, Alnylam Win First RNAi Approval for Hemophilia A and B
Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...
BioPharma Dive7d
FDA approves first-of-its-kind RNA drug for hemophilia
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare bleeding disorder.
FDA approves Qfitlia to cut bleeding episodes in patients with hemophilia
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
Medscape7d
Fitusiran Approved for Hemophilia A, B
The US Food and Drug Administration has approved fitusiran for bleeding prophylaxis in hemophilia A and B with or without ...
GlobalData on MSN5d
Sanofi’s Qfitlia approved by FDA as first haemophilia therapy for all patients
Despite a haemophilia market bustling with rivals, Qfitlia’s broad label and favourable dosing regimen could give it an upper ...
FDA Approves Sanofi's Hemophilia Drug
The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...
Sanofi’s Easier to Use Hemophilia Drug Approved by US FDA
Sanofi’s treatment for hemophilia that can be administered as infrequently as once every other month, was approved by the US ...
Pharmaceutical Technology on MSN1d
FDA awards ODD status to Sanofi’s rilzabrutinib for two rare conditions
Sanofi's reversible BTK inhibitor rilzabrutinib has gained the US Food and Drug Administration’s (FDA) orphan drug ...